SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
President and Chief Executive Officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the second quarter 2014.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast, please log
on to www.halozyme.com approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. For those without access to the Internet, the live call
may be accessed by phone by calling (866) 710-0179 (domestic
callers) or (334) 323-7224 (international callers) using passcode
769890. A telephone replay will be available shortly after the call
by dialing (877) 919-4059 (domestic callers) or (334) 323-0140
(international callers) using replay ID number 71625396.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated
to developing and commercializing innovative products that advance
patient care. With a diversified portfolio of enzymes that target
the extracellular matrix, the Company's research focuses primarily
on a family of human enzymes, known as hyaluronidases, which
increase the absorption and dispersion of biologics, drugs and
fluids. Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes, and dermatology that have significant unmet
medical need. The Company markets Hylenex®
recombinant (hyaluronidase human injection) and has partnerships
with Roche, Pfizer, and Baxter.
Halozyme is headquartered in San Diego,
CA. For more information on how we are innovating, please
visit our corporate website at www.halozyme.com.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
SOURCE Halozyme Therapeutics, Inc.